Comparison · NCT02049814-sae
Metformin + Voglibose 0.2 mg vs Metformin + Acarbose 50 mg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Metformin + Voglibose 0.2 mg vs Metformin + Acarbose 50 mg: serious adverse events. Trial comparisons, record NCT02049814-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02049814-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0121 | 0.00412 | 0.035 | wilson | |
| Risk in group 2 | 0.0204 | 0.00875 | 0.0469 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00831 | -0.036 | 0.0173 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.593 | 0.143 | 2.45 | log | |
| Odds ratio, group 1 over group 2 | 0.588 | 0.139 | 2.49 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Metformin + Voglibose 0.2 mg than on Metformin + Acarbose 50 mg | 120 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Metformin + Voglibose 0.2 mg | Metformin tablets, at the maximum tolerated dose ≥1000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12. | 3 | 248 | EG000 |
| Group 2 | Metformin + Acarbose 50 mg | Metformin tablets, at the maximum tolerated dose ≥1000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12. | 5 | 245 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to Week 14
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes
- NCT number
- NCT02049814
- Phases
- PHASE4
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Metformin, Voglibose, Acarbose
- Lead sponsor
- Takeda
- Results first posted
- 2019-02-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02049814?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02049814-sae